secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001628280-24-047406
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma Q3 net loss $36.7M; positive Phase 2 CN data; XOLREMDI launch underway
--------------------------------------------------------------------------------

- Q3 net loss $36.7M vs $2.3M loss in Q3 2023; includes $1.9M non-cash loss on warrant liability.
- Net product revenue of $0.6M from XOLREMDI (mavorixafor) for WHIM syndrome, launched April 2024.
- Positive Phase 2 results: mavorixafor durably increased absolute neutrophil counts and enabled G-CSF reduction in chronic neutropenia.
- Phase 3 4WARD trial on track to fully enroll mid-2025; regulatory approvals in ~85% of targeted countries.
- Cash $135.8M, sufficient into late 2025 (excludes potential XOLREMDI revenue).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024047406/0001628280-24-047406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024047406/xfor-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-047406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer